gdc
PSSGuide_2021
Prostate Cancer

Drugs for Prostate Cancer

Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.

Emcyt (estramustine phosphate sodium) Capsules

Drug company: Pfizer
877-744-5675

Emcyt capsules are used as palliative treatment of patients with metastatic and/or progressive prostate cancer.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Emcyt:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Emcyt, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Pfizer Savings Program

Through this program, uninsured patients, regardless of income, will see an estimated savings of 36% to 75% on their medication costs when purchased at a participating retail pharmacy.

Erleada (apalutamide) Tablets

Drug company: Janssen Biotech
833-375-3232

Erleada is an androgen receptor inhibitor used for the treatment of patients with non-metastatic castration-resistant prostate cancer. Erleada is also used for the treatment of patients with metastatic castration-sensitive prostate cancer.

Jannsen CarePath offers 2 financial assistance programs for patients who have been prescribed Erleada:

Janssen CarePath Savings Program

Eligible patients who have private insurance may pay only $0 per month for Erleada, with an annual benefit up to $15,000. The savings may apply toward copay, co-insurance, or deductible, depending on the patient’s health insurance plan.

Johnson & Johnson Patient Assistance Foundation

This program provides Erleada free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or are enrolled in Medicare Part D.

Jevtana (cabazitaxel)

Drug company: Sanofi Genzyme
833-930-2273

Jevtana is a microtubule inhibitor used, in combination with prednisone, for the treatment of patients with hormonerefractory metastatic prostate cancer, after treatment with a docetaxel-based regimen.

Sanofi Genzyme offer 2 financial assistance programs for patients who are prescribed Jevtana:

CareASSIST Copay Program

Eligible patients who have commercial insurance may pay as little as $0 for Jevtana, up to a $25,000 benefit per year. Patients must have commercial or private insurance, including state or federal employee plans and health insurance exchanges.

CareASSIST Patient Assistance Program

Patients who are uninsured or are underinsured may be eligible to receive Jevtana at no cost. To be eligible for this program, the patient’s annual household income must not be more than $100,000, or 500% of the federal poverty level. Patients enrolled in Medicare Part B who have no supplemental insurance may also be eligible to receive Jevtana through this program.

Lynparza (olaparib)

Drug company: AstraZeneca
844-275-2360

Lynparza is a PARP inhibitor used for treatment of patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR gene mutation, as determined by an FDA-approved test, in men whose disease progressed after enzalutamide or abiraterone therapy.

AstraZeneca offers 2 financial assistance programs for patients who have been prescribed Lynparza:

Lynparza Co-pay Savings Program

The patient’s out-of-pocket costs may vary, but this program aims for eligible patients to pay $0 per month for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare limited income subsidy.

Patients with Medicare Part B coverage should call 800-292- 6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Nubeqa (darolutamide)

Drug company: Bayer
833-337-3833

Nubeqa is an androgen receptor inhibitor used for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Bayer offers 3 financial assistance programs for patients who have been prescribed Nubeqa:

Nubeqa Free Trial Program

Through this program, new patients who have been prescribed Nubeqa will receive this medication at no cost for 2 months.

Nubeqa $0 Co-Pay Program

Eligible patients who have private insurance may pay $0 copay for Nubeqa, with a maximum annual benefit of $25,000.

Bayer US Patient Assistance Foundation

This foundation provides Nubeqa free of charge to uninsured or underinsured patients who meet specific financial criteria.

Premarin (conjugated estrogens) Tablets

Drug company: Pfizer
877-744-5675

Premarin is a mixture of estrogens used as palliative treatment of patients with advanced androgen-dependent prostate cancer.

Pfizer Oncology Together offers 3 financial assistance programs for patients using Premarin:

Premarin Savings Card

With this savings card, patients who are not fully reimbursed for Premarin can pay as little as $30, with a savings of up to $55 per prescription fill. The card is limited to 12 offers and a maximum savings of $660 per calendar year.

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Premarin, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Free Medicine Through Health Centers and Hospitals

Uninsured patients may be eligible to receive Premarin tablets for free at select health centers and hospitals nationwide. Drug availability varies by institution and by patient’s eligibility.

Provenge (sipuleucel-T)

Drug company: Dendreon
877-336-3736

Provenge is an autologous cellular immunotherapy used for the treatment of patients with metastatic castrationresistant (hormone-refractory) prostate cancer.

Dendreon offers 3 financial assistance programs for patients using Provenge:

PROvide Commercial Co-pay Program

This program supports eligible, insured patients by covering any combination of cost (copays, co-insurance, or deductibles) to a maximum of $6,000 over 3 Provenge treatments.

Co-pay Assistance for Patients with Medicare

This program helps eligible patients with Medicare pay for copays, co-insurance, and deductibles.

Provenge Uninsured Patient Program

Patients who are uninsured and who have an adjusted gross income of $150,000 a year or less may be able to get Provenge at no cost through this program.

Rubraca (rucaparib) Tablets

Drug company: Clovis Oncology
844-779-7707

Rubraca is a PARP inhibitor used for the treatment of adults with metastatic castration-resistant prostate cancer and a deleterious (germline and/or somatic) BRCA mutation, as detected by an FDA-approved test, who have received androgen receptor therapy and a taxane-based chemotherapy.

Clovis Oncology provides 3 financial assistance programs for patients who have been prescribed Rubraca:

Rubraca $0 Co-Pay Program

Patents with private insurance pay $0 copay for Rubraca through this program, with a maximum annual assistance up to $24,000.

Rubraca Connections Patient Assistance Program

Patients who are uninsured or underinsured who meet certain financial and residential eligibility requirements may qualify to receive Rubraca for free.

Rubraca Connections QuickStart Program

Eligible patients with private insurance who have insurance challenges can receive a 15-day supply of Rubraca and up to 90 days through this program.

Trelstar (triptorelin pamoate) for Injectable Suspension

Drug company: Allergan
844-424-6727

Trelstar is a gonadotropin-releasing hormone agonist used as palliative treatment of advanced prostate cancer.

Allergan offers 1 financial assistance program for patients using Trelstar:

Allergan Patient Assistance Program

Patients who cannot afford the cost of Trelstar and meet other eligibility requirements may qualify for free medication. Eligible applicants will be enrolled for 12 months and a 90-day supply of medication will be immediately shipped to the physician. Medicare Part D applicants must have been denied low income subsidy and will only be enrolled until the end of the calendar year.

Xofigo (radium Ra 223 dichloride) Injection

Drug company: Bayer
855-696-3446

Xofigo is an alpha particle-emitting radioactive therapeutic agent used for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

Bayer offers 2 financial assistance programs for patients using Xofigo:

Xofigo Access Services $0 Copay

This program provides privately insured patients with a Commercial Copay Assistance ID card so that the copay for Xofigo is $0.

Xofigo Access Services Financial Assistance Program

This program provides Xofigo free of charge for eligible patients who are uninsured or are without coverage for Xofigo. Applicants must meet certain financial criteria.

Xtandi (enzalutamide) Tablets

Drug company: Astellas Pharma
855-898-2634

Xtandi is an androgen receptor inhibitor used for the treatment of patients with castration-resistant prostate cancer. Xtandi is also used for the treatment of patients with metastatic castration-sensitive prostate cancer.

Astellas Pharma offers 3 financial assistance programs for patients using Xtandi:

XTANDI Patient Savings Program

This program allows eligible, privately insured patients to pay as little as $0 per prescription of Xtandi, with a benefit of up to $25,000 annually.

XTANDI Quick Start+ Program

Eligible, new patients awaiting coverage determination will be provided a free 14-day supply of Xtandi.

Astellas Patient Assistance Program

Patients who do not have prescription coverage for Xtandi may receive their medication at no cost through this program. Applicants must have an annual household income of less than $100,000.

Yonsa (abiraterone acetate) Tablets

Drug company: Sun Pharma
855-449-6672

Yonsa is a CYP17 inhibitor used, in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer.

Sun Pharma’s Yonsa Support offers 3 financial assistance programs for patients who have been prescribed Yonsa:

Yonsa Copay Program

Eligible patients who have private insurance may pay as little as $10 for their prescription of Yonsa through this program, with a maximum benefit of $5,000 per prescription, and $12,000 per year.

Yonsa Early Access Program

Patients facing a delay in medication coverage will be enrolled in this program and will receive free Yonsa for up to 30 days.

Yonsa Patient Assistance Program

For eligible patients who do not have commercial (private) insurance, this program will assist with the cost of Yonsa.

Zoladex (goserelin acetate implant)

Drug company: TerSera Therapeutics
855-686-8725

Zoladex is a gonadotropin-releasing hormone agonist used, in combination with flutamide, for the treatment of patients with localized prostate cancer. Zoladex is also used as a palliative treatment of advanced prostate cancer.

TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Zoladex:

Zoladex Co-Pay Card

Eligible patients with private insurance may pay as little as $0 for their prescription of Zoladex, with a maximum benefit of $2,000 per year. Eligible, cash-paying patients whose prescriptions are not paid by any government programs will receive up to $300 off each 1-month supply of Zoladex.

Zoladex Patient Assistance Program

For eligible patients who don’t have commercial insurance, this program may provide free Zoladex for up to 1 year before renewal is required. The medicine is sent in a 90-day supply to the patient’s home or the doctor’s office.

Zytiga (abiraterone acetate)

Drug company: Janssen Biotech
855-998-4421

Zytiga is a CYP17 inhibitor used, in combination with prednisone, for the treatment of patients with metastatic castration- resistant prostate cancer. Zytiga is also used, in combination with prednisone, for patients with metastatic high-risk castration-sensitive prostate cancer.

Janssen Biotech offers 2 financial assistance programs for patients using Zytiga:

Janssen CarePath Savings Program

With this card, privately insured patients will pay no more than $10 monthly for their medicine, with a $12,000 maximum benefit per calendar year.

Johnson & Johnson Patient Assistance Foundation

This program provides Zytiga free of charge for up to 12 months to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Table. Drugs Prescribed for Prostate Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Emcyt (estramustine phosphate sodium) Capsules
  • Drug company
  • Pfizer
  • Indication
  • Palliative treatment of metastatic and/or progressive prostate cancer
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675

    Pfizer Savings Program
    877-744-5675


    Drug name (generic name)
  • Jevtana (cabazitaxel)
  • Drug company
  • Sanofi Genzyme
  • Indication
  • Treatment of hormone-refractory metastatic prostate cancer, in combination with prednisone, after a docetaxel-based regimen
  • Patient support services
  • CareASSIST Copay Program
    833-930-2273

    CareASSIST Patient Assistance Program
    833-930-2273

    Drug name (generic name)
  • Lynparza (olaparib)
  • Drug company
  • AstraZeneca
  • Indication
  • Treatment of patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR gene mutation, as determined by an FDA-approved test, in men whose disease progressed after enzalutamide or abiraterone therapy
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363





    Drug name (generic name)
  • Trelstar (triptorelin pamoate) for Injectable Suspension
  • Drug company
  • Allergan
  • Indication
  • Palliative treatment of advanced prostate cancer
  • Allergan Patient Assistance Program
  • Allergan Patient Assistance Program
    844-424-6727




    Drug name (generic name)
  • Zoladex (goserelin acetate implant)
  • Drug company
  • TerSera Therapeutics
  • Indication
  • Treatment of localized prostate cancer, in combination with flutamide

    Palliative treatment of advanced prostate cancer
  • Patient support services
  • Zoladex Co-Pay Card
    844-864-3014

    Zoladex Patient Assistance Program
    855-686-8725

    Drug name (generic name)
  • Zytiga (abiraterone acetate)
  • Drug company
  • Janssen Biotech
  • Indication
  • Treatment of metastatic castrationresistant prostate cancer, in combination with prednisone

    Treatment of metastatic high-risk castration-sensitive prostate cancer, in combination with prednisone
  • Patient support services
  • Janssen CarePath Savings Program
    855-998-4421

    Johnson & Johnson Patient Assistance Foundation
    800-652-6227

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country